```
     FILE 'REGISTRY' ENTERED AT 17:31:01 ON 29 SEP 2007
L1             0 S RIBOSE AND CARNITINE
L2             7 S RIBOSE AND MAGNESIUM

     FILE 'CAPLUS' ENTERED AT 17:32:45 ON 29 SEP 2007
L3            87 S RIBOSE AND CARNITINE
L4            24 S L3 AND MAGNESIUM
L5             2 S L4 AND DEPRESSION
L6            22 S L4 NOT L5

=> d his

     (FILE 'HOME' ENTERED AT 17:30:31 ON 29 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 17:31:01 ON 29 SEP 2007
L1             0 S RIBOSE AND CARNITINE
L2             7 S RIBOSE AND MAGNESIUM

     FILE 'CAPLUS' ENTERED AT 17:32:45 ON 29 SEP 2007
L3            87 S RIBOSE AND CARNITINE
L4            24 S L3 AND MAGNESIUM
L5             2 S L4 AND DEPRESSION
L6            22 S L4 NOT L5
```

Copy to be Scanned

10/590,986

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau1831ec

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	BEILSTEIN updated with new compounds
NEWS 12	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 13	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 14	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 15	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16	AUG 27	USPATOLD now available on STN
NEWS 17	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19	SEP 13	FORIS renamed to SOFIS
NEWS 20	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 21	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 22	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 23	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:30:31 ON 29 SEP 2007

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:31:01 ON 29 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2007 HIGHEST RN 948877-55-2
DICTIONARY FILE UPDATES: 28 SEP 2007 HIGHEST RN 948877-55-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s ribose and carnitine
4223 RIBOSE
987 CARNITINE
L1 0 RIBOSE AND CARNITINE

=> s ribose and magnesium
4223 RIBOSE
99998 MAGNESIUM
L2 7 RIBOSE AND MAGNESIUM

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.15	21.36

FILE 'CAPLUS' ENTERED AT 17:32:45 ON 29 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

```
FILE COVERS 1907 - 29 Sep 2007  VOL 147 ISS 15
FILE LAST UPDATED: 28 Sep 2007  (20070928/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 17:30:31 ON 29 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 17:31:01 ON 29 SEP 2007
L1            0 S RIBOSE AND CARNITINE
L2            7 S RIBOSE AND MAGNESIUM

     FILE 'CAPLUS' ENTERED AT 17:32:45 ON 29 SEP 2007

=> s ribose and carnitine
         28571 RIBOSE
         11361 CARNITINE
L3          87 RIBOSE AND CARNITINE

=> s l3 and magnesium
        498893 MAGNESIUM
L4          24 L3 AND MAGNESIUM

=> s l4 and depression
         84294 DEPRESSION
L5           2 L4 AND DEPRESSION

=> s l4 not l5
L6          22 L4 NOT L5

=> d l5 ed ibib abs 1-2

L5   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
ED   Entered STN:  29 Sep 2005
ACCESSION NUMBER:         2005:1042077  CAPLUS
DOCUMENT NUMBER:          143:319176
TITLE:                    D-ribose for improving depression
                          -like symptoms
INVENTOR(S):              Yamamura, Michio; Hayashida, Koukichi; Tsuchida,
                          Toshito
PATENT ASSIGNEE(S):       Tanabe Seiyaku Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 30 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2005089774         A1    20050929    WO 2005-JP5452           20050317
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
```

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1734974 A1 20061227 EP 2005-721429 20050317
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

US 2007191287 A1 20070816 US 2006-590986 20060829

PRIORITY APPLN. INFO.: JP 2004-78521 A 20040318
JP 2004-126176 A 20040422
JP 2004-287677 A 20040930
WO 2005-JP5452 W 20050317

AB An agent for improving depression-like symptoms comprises D-ribose, which may improve and alleviate various symptoms such as hypobulia, general fatigue, sluggishness, enervation, deterioration in concentration, memory impairment, abnormal sensation/obtundation such as impaired sight, decline in thinking power, indefinite complaint, drop in operation efficiency, or feeling of malaise, etc.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 05 Jul 1995
ACCESSION NUMBER: 1995:655227 CAPLUS
DOCUMENT NUMBER: 123:40968
TITLE: Combination of sugars with amino acids and other drugs
INVENTOR(S): Naito, Albert
PATENT ASSIGNEE(S): USA
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 652012	A1	19950510	EP 1993-308852	19931105

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: EP 1993-308852 19931105

AB A material which has the ability to effect it's passage, at least in part, and the ability to transport other materials through the blood-brain barrier, includes any one or more pure sugars or pure amino sugars from the group consisting of meso-erythritol, xylitol, D-galactose, D-lactose, D-xylose, dulcitol, myo-inositol, L-fructose, D-mannitol, sorbitol, D-glucose, D-(+)-arabinose, D-(-)-arabinose, cellobiose, D-(+)-maltose, D-(+)-raffinose, L-(+)-rhamnose, D-(+)-melibiose, D-(-)-ribose, adonitol, D-(+)-arabitol, L-(-)-arabitol, D-(+)-fucose, L-(-)-fucose, D(-)-lyxose, L-(+)-lyxose, L-(-)-lyxose, D-(+)-glucosamine, D-mannosamine, and D-galactosamine; and any one or more amino acids from the group consisting of arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, glutamine, lysine, tryptophan, tyrosine, valine, and taurine. For use in the research or treatment of a subject that material is combined with one or more of the substances β-carotene, xanthophyll, lecithin, calcium, somatostatin, vasopressin, endorphin, enkephalin, acetyl-L-carnitine, GABA, dynorphin, L--tryptophan, choline, thiamine, pyridoxine, niacin, L-arginine, hydroxyproline, NGF, methionine, cystine, potassium, phosphorus, chlorine, sodium, vitamin A, B, C, D and E, tricalcium phosphate, linolenic acid, oats, rice, apple fiber, acidophilus, and selenium.

=> d his

(FILE 'HOME' ENTERED AT 17:30:31 ON 29 SEP 2007)

FILE 'REGISTRY' ENTERED AT 17:31:01 ON 29 SEP 2007
L1 0 S RIBOSE AND CARNITINE
L2 7 S RIBOSE AND MAGNESIUM

FILE 'CAPLUS' ENTERED AT 17:32:45 ON 29 SEP 2007
L3 87 S RIBOSE AND CARNITINE
L4 24 S L3 AND MAGNESIUM
L5 2 S L4 AND DEPRESSION
L6 22 S L4 NOT L5

=> d l6 ed ibib abs 1-22

L6 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 27 Jul 2007
ACCESSION NUMBER: 2007:817105 CAPLUS
DOCUMENT NUMBER: 147:182868
TITLE: Use of DNA microarrays, gene expression profiles, and computer models for predicting cardiotoxicity of substances
INVENTOR(S): Mendrick, Donna L.; Johnson, Kory R.; Daniels, Kellye K.; Porter, Mark W.
PATENT ASSIGNEE(S): Gene Logic, Inc., USA
SOURCE: PCT Int. Appl., 203pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007084187	A2	20070726	WO 2006-US33712	20060828

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-711444P P 20050826
AB The present invention includes methods of predicting cardiotoxicity of test agents and methods of generating cardiotoxicity prediction models using algorithms for analyzing quant. gene expression information. The invention also includes microarrays, computer systems comprising the toxicity prediction models, as well as methods of using the computer systems by remote users for determining the toxicity of test agents.

L6 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 24 May 2007
ACCESSION NUMBER: 2007:560639 CAPLUS
DOCUMENT NUMBER: 146:481114
TITLE: Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose.
INVENTOR(S): Pietro, Pola
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy

SOURCE: U.S. Pat. Appl. Publ., 6pp., Cont.-in-part of U.S. Ser. No. 48,590.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007116743	A1	20070524	US 2006-604390	20061127
IT 2000RM0323	A1	20011214	IT 2000-RM323	20000614
WO 2001095915	A1	20011220	WO 2001-IT283	20010601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003108537	A1	20030612	US 2002-48590	20020201

PRIORITY APPLN. INFO.:

IT 2000-RM323	A	20000614
WO 2001-IT283	W	20010601
US 2002-48590	A2	20020201

AB A health food/dietary supplement is disclosed suitable for enhancing muscular energy metabolism, comprising as its characterizing active ingredients an alkanoyl L-carnitine and ribose.

L6 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 27 Apr 2007
ACCESSION NUMBER: 2007:461147 CAPLUS
DOCUMENT NUMBER: 146:416614
TITLE: Methods and compositions for biomarkers associated with change in physical performance
INVENTOR(S): Kalns, John; Christy, Robert
PATENT ASSIGNEE(S): Hyperion Biotechnology, Inc., USA
SOURCE: PCT Int. Appl., 82pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007047041	A2	20070426	WO 2006-US37489	20060927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

US 2005-726792P	P	20051014
US 2006-808165P	P	20060524

AB The present invention provides methods and compns. for detecting an improvement in the performance of a phys. or athletic activity and/or in a

cognitive activity in a subject upon administration to the subject of a performance enhancing material and/or upon contact of the subject with a performance enhancing material and/or upon implementation of a performance enhancing activity by the subject by detecting in the subject a change in a biomarker associated with phys. or athletic activity and/or cognitive activity.

L6 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 01 Dec 2006
ACCESSION NUMBER: 2006:1256671 CAPLUS
DOCUMENT NUMBER: 146:33048
TITLE: Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
INVENTOR(S): Naidu, A. Satyanarayan; Naidu, A. G. Tezus; Naidu, A. G. Sreus
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006269535	A1	20061130	US 2006-442473	20060526
PRIORITY APPLN. INFO.:			US 2005-686257P	P 20050531

AB Formulations are provided for the trigger and release of bioenergy. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber and includes at least one metal-binding protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compns. can be administered orally in a variety of forms. A formulation for diabetes control contained elemental complex 0.1, coenzyme complex 0.1, trigger complex 11.2, functional ingredients 10.4, and excipients 78.2%.

L6 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 08 Dec 2005
ACCESSION NUMBER: 2005:1283320 CAPLUS
DOCUMENT NUMBER: 144:22242
TITLE: Fatigue-improving agent containing D-ribose with magnesium salts, amino acids and/or carnitine
INVENTOR(S): Tsuchida, Toshito; Hayashida, Kokichi
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005336176	A	20051208	JP 2005-130676	20050428
PRIORITY APPLN. INFO.:			JP 2004-133203	A 20040428

AB The invention relates to an agent characterized by containing D-ribose , and a magnesium salt, amino acids and/or carnitine for treatment of body fatigue and/or improving body energy level, suitable for use in a health food composition For example, anti-fatigue effect of a composition containing D-ribose with branched amino acids in forced swimming mice was examined

L6 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 19 Aug 2005
ACCESSION NUMBER: 2005:823153 CAPLUS
DOCUMENT NUMBER: 143:210893
TITLE: Compositions and methods for timed release of water-soluble nutritional supplements
INVENTOR(S): Romero, Jaime
PATENT ASSIGNEE(S): Colombia
SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005181047	A1	20050818	US 2004-782245	20040218
US 2005181048	A1	20050818	US 2004-910787	20040803
US 2005181044	A1	20050818	US 2004-930560	20041209
WO 2005079764	A1	20050901	WO 2005-US4890	20050216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2005002357	A	20070221	BR 2005-2357	20050621

PRIORITY APPLN. INFO.: US 2004-782245 A2 20040218
US 2004-910787 A2 20040803

AB The present invention relates to compns. of and methods for producing timed or retarded release formulations that contain glucosamine sulfate, beta-(1,4)-2-amino-2-deoxy-D-glucose, and chondroitin, (C14H19NO14SNa2)n; N-acetylchondrosanine (2-acetamide-2-deoxy-D-galactopyranose) and D-guluronic acid copolymer and/or their dietary and nutraceutically acceptable salts of the same and/or hydrates of the active substance that provide a timed release formulation of the active substance.

L6 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 12 Aug 2005
ACCESSION NUMBER: 2005:735222 CAPLUS
DOCUMENT NUMBER: 143:189510
TITLE: Culture media compositions free of fetal bovine serum
INVENTOR(S): O'Daly, Jose A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005176144	A1	20050811	US 2004-773578	20040206
AU 2005213389	A1	20050825	AU 2005-213389	20050204
CA 2555869	A1	20050825	CA 2005-2555869	20050204
WO 2005076905	A2	20050825	WO 2005-US3494	20050204

WO 2005076905 A3 20060504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1718729 A2 20061108 EP 2005-712805 20050204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU
BR 2005007483 A 20070717 BR 2005-7483 20050204
JP 2007521027 T 20070802 JP 2006-552247 20050204
US 2006194322 A1 20060831 US 2006-406164 20060418
PRIORITY APPLN. INFO.: US 2004-773578 A 20040206
WO 2005-US3494 W 20050204

AB A cell culture growth media free of Fetal Bovine Serum for use with parasitic organisms. The media includes calcium chloride, sodium bicarbonate, potassium chloride, sodium chloride, monosodium phosphate, glucose, hepes, ferric nitrate, magnesium sulfate, tricine, d-ribose, 2-deoxy ribose, adenosine-5-triphosphate (ATP), 2-deoxyadenylic acid (d-AMP), 5'-thymidylic acid (TMP), 2'-deoxyicitidine-5 monophosphate, d- 2'-deoxyuridine-5-monophosphate, d-2'-deoxyguanilic Acid (d-GMP), aspartic acid, glutamic acid, 1-alanine, arginine, carnosine, cysteine, cystine, glutamine, glycine, histidine, iso-leucine, leucine, lysine, methionine, ornitine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ascorbic acid, biotine (H), carnitine, cholecalciferol, choline chloride, cyanocobalamine (B12), ergocalciferol, folic acid, myo-inositol, menadione, nicotinamide, PABA, pantothenate, pyridoxal, pyridoxamine, pyridoxine, retinol (A), riboflavin (B2), Thiamine (B1), 6,8 Thiotic acid, alfa-tocoferol, 3-phytylmenadione (K1), tetrahydrofolic acid, hemin from porcine, and nanopure water.

L6 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 30 Apr 2004
ACCESSION NUMBER: 2004:352956 CAPLUS
DOCUMENT NUMBER: 140:363037
TITLE: Formulations for topical delivery of bioactive substances and methods for their use
INVENTOR(S): Vromen, Jacob
PATENT ASSIGNEE(S): Australian Importers Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004081681	A1	20040429	US 2002-281062	20021025
US 7241456	B2	20070710		
CA 2543370	A1	20040513	CA 2003-2543370	20031015
WO 2004039348	A1	20040513	WO 2003-US32638	20031015

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003282834	A1	20040525	AU 2003-282834		20031015
EP 1558206	A1	20050803	EP 2003-774832		20031015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
US 2007071711	A1	20070329	US 2006-535213		20060926
PRIORITY APPLN. INFO.:			US 2002-281062	A	20021025
			WO 2003-US32638	W	20031015

AB The invention relates to topical delivery of bioactive agents. More particularly, the invention relates to anhydrous formulations for percutaneous absorption. The invention provides formulations that allow efficient topical delivery of high concns. of bioactive substances for percutaneous absorption. The formulations according to the invention are generally non-irritating to the skin. A preferred topical formulation comprises (1) anhydrous media containing glycerin, propylene glycol, capric/caprylic triglyceride, cetearyl alc., d-tocopherol, ascorbyl palmitate, thiodipropionic acid, BHT, phenoxyethanol, and parabens and (2) bioactive substances containing micronized niacinamide, micronized acetylsalicylic acid, and micronized ascorbic acid.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 17 Mar 2004
ACCESSION NUMBER: 2004:213413 CAPLUS
DOCUMENT NUMBER: 141:22606
TITLE: Protein hydrolyzate containing biologically active substances with application in food, feed, pharmaceuticals, fertilizers, and cosmetics
INVENTOR(S): Makarov, N. V.; Novikov, V. I.
PATENT ASSIGNEE(S): Russia
SOURCE: Russ., No pp. given
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2221456	C1	20040120	RU 2003-106447	20030311
PRIORITY APPLN. INFO.:			RU 2003-106447	20030311

AB A protein hydrolyzate is obtained by acid hydrolysis of animal products, with subsequent neutralization, filtration, and drying. Starting materials may include carcasses of livestock or fish, albumins, blood, meat or fish. The hydrolyzate comprises ≤25% peptides with mol. weight <3000 Da and an optical activity [α]20D of 5-15. The ratio of amino nitrogen:fatty acids:carbohydrates = (10-30):(0.2-2):(0.4-5) and the product also contains sodium, chromium, nickel, cobalt, selenium, calcium, potassium, sulfur, phosphorus, chlorine, iron, zinc, copper, and manganese. The hydrolyzate, containing biol. active substances, may be used in the production of nutritional supplements and food (including dairy products, confectionery, bakery products, fats and oils, sauces, alc. and nonalcoholic beverages, fish and meat products, pasta products, chewing gum, and beer), feed supplements, pharmaceutical and veterinary prepns., fertilizers, as an activator of microbiol. processes, and in perfumes, cosmetics, and personal-care items. The product may also improve the storage life and stability of foods, enhancing structural and rheol. properties in combination with high moisture-retaining capacity.

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 16 Mar 2004
ACCESSION NUMBER: 2004:209240 CAPLUS
DOCUMENT NUMBER: 141:406482
TITLE: Global expression analysis of the characterization of lysin production in Corynebacterium glutamicum
AUTHOR(S): Sindelar, Georg
CORPORATE SOURCE: Institut fuer Biotechnologie, Germany
SOURCE: Berichte des Forschungszentrums Juelich (2003), Juel-4092, 1-146
CODEN: FJBEE5; ISSN: 0944-2952
DOCUMENT TYPE: Report
LANGUAGE: German
AB New target genes and operons, resp. for the improvement of Lys production by Corynebacterium glutamicum were identified applying genome-wide gene expression anal. by DNA chips. The gene expression patterns of a wild-type strain and of a potent production strain MH20-22B obtained by mutagenesis were compared. The differences in the expression patterns were assigned to the deregulated aspartate kinase, to the Leu auxotrophy, and to further, unknown mutations. In C. glutamicum MH20-22B, 7 genes were up-regulated. Over-expression of the gene of a Me transferase of the uroporphyrin-II-C-Me transferase group, of a putative operon bearing the ammonium transporter Amt, of a putative Orn cyclodecarboxylase, and of a putative sarcosine oxidase caused an increase in Lys production by 45%.
REFERENCE COUNT: 189 THERE ARE 189 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 05 Mar 2004
ACCESSION NUMBER: 2004:182238 CAPLUS
DOCUMENT NUMBER: 140:193117
TITLE: Metabolic uncoupling therapy
INVENTOR(S): McCleary, Edward Larry
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 749,584.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043013	A1	20040304	US 2003-462958	20030617
US 2002132219	A1	20020919	US 2000-749584	20001228
US 6579866	B2	20030617		
US 2005002992	A1	20050106	US 2004-890067	20040712
US 2005095233	A1	20050505	US 2004-987108	20041112
US 2005129783	A1	20050616	US 2004-986924	20041112
US 2005181069	A1	20050818	US 2005-88388	20050323
US 2006014773	A1	20060119	US 2005-223719	20050909
US 2006062864	A1	20060323	US 2005-271350	20051112
US 2007160590	A1	20070712	US 2007-703446	20070206
PRIORITY APPLN. INFO.:			US 2000-749584 A2	20001228
			US 2001-837562 A2	20010419
			US 2003-462958 A2	20030617
			US 2003-616674 A2	20030710
			US 2003-520466P P	20031114
			US 2004-536286P P	20040113
			US 2004-890067 A2	20040712
			US 2004-986924 A2	20041112

US 2004-630529P	P	20041122
US 2005-49244	A2	20050202
US 2005-111542	A2	20050421

AB A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy (MUT) comprises: analyzing a specific physiol. process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 08 Aug 2003
ACCESSION NUMBER: 2003:609887 CAPLUS
DOCUMENT NUMBER: 139:148844
TITLE: Energy fitness water containing Garcinia citrate, ribose, chromium and other nutrients.
INVENTOR(S): Choudhry, Muhammad S.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 4 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003148016	A1	20030807	US 2002-67636	20020207
PRIORITY APPLN. INFO.:			US 2002-67636	20020207

AB A method of making an alternative bottled water comprising as main ingredients, D-ribose, L-carnitine, coenzyme Q10, ATP, Taurine, Garcinia cambogia, chromium polynicotinate, or chromium picolinate with or without L-aspartic acid to provide cardiovascular fitness and overall phys. energy. Said energy fitness water may also contain a non-nutritive or nutritive sweetener, aroma and coloring. The bottled water prepared from these ingredients has pH range from 3.5 to 7.0, dependent on processing and packaging of the bottled water.

L6 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 06 Dec 2002
ACCESSION NUMBER: 2002:928020 CAPLUS
DOCUMENT NUMBER: 138:8355
TITLE: Composition and method for normalizing impaired or deteriorating neurological function
INVENTOR(S): McCleary, Edward Larry
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002182196	A1	20021205	US 2001-837562	20010419
US 6964969	B2	20051115		
US 2005129783	A1	20050616	US 2004-986924	20041112
US 2006014773	A1	20060119	US 2005-223719	20050909
PRIORITY APPLN. INFO.:			US 2001-837562 A2	20010419
			US 2003-462958 A2	20030617
			US 2003-616674 A2	20030710

US 2003-520466P	P	20031114
US 2004-536286P	P	20040113
US 2004-890067	A2	20040712
US 2004-630529P	P	20041122
US 2005-49244	A2	20050202

AB A nutritional supplement composition for normalizing impaired or deteriorating neurol. function in humans is composed of: at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body, at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of: at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and/or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining Me metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. A method for normalizing impaired neurol. function in humans modulating nutrient partitioning in a human involves administering the aforementioned composition to the human, preferably on a daily basis, for a therapeutically effective period of time. Preferably, the method further involves having the human follow a stress reduction program, and/or a cognitive retraining program, and/or a dietary program designed to maximize insulin and glucose metabolism

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 08 Mar 2002
ACCESSION NUMBER: 2002:171618 CAPLUS
DOCUMENT NUMBER: 136:215851
TITLE: Method for preparing a mixture that can be granulated, especially carnitine-magnesium hydroxycitrate
INVENTOR(S): Fuhrmann, Martin; Pianzola, Daniel
PATENT ASSIGNEE(S): Lonza Ag, Switz.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017735	A2	20020307	WO 2001-EP9962	20010829
WO 2002017735	A3	20020912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 200189849	A	20020313	AU 2001-89849	20010829
EP 1326502	A2	20030716	EP 2001-969667	20010829

EP 1326502	B1	20050518				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
JP 2004507479	T	20040311	JP 2002-522720		20010829	
AT 295690	T	20050615	AT 2001-969667		20010829	
PT 1326502	T	20050930	PT 2001-969667		20010829	
ES 2242770	T3	20051116	ES 2001-1969667		20010829	
US 2003176514	A1	20030918	US 2003-362730		20030514	
US 2004167219	A1	20040826	US 2004-785013		20040225	
US 7230131	B2	20070612				
PRIORITY APPLN. INFO.:			EP 2000-118656	A	20000829	
			WO 2001-EP9962	W	20010829	
			US 2003-362730	A3	20030514	

AB The invention relates to a method for preparing, from at least one hygroscopic substance, mixts. that can be granulated and that have little hygroscopicity. The invention further relates to the corresponding mixts., especially carnitine-magnesium citrate and carnitine-magnesium hydroxycitrate.

L6 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 22 Feb 2002
ACCESSION NUMBER: 2002:143204 CAPLUS
DOCUMENT NUMBER: 136:189383
TITLE: A water-free transdermal delivery system
INVENTOR(S): Dransfield, Charles William
PATENT ASSIGNEE(S): Australia
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002022052	A1	20020221	US 2001-863764		20010524
PRIORITY APPLN. INFO.:			AU 2000-6691	A	20000406
			AU 2000-8885	A	20000721

AB A transdermal or transepithelial composition substantially free of water comprises a biol. active agent in the form of microfined particles, sized less than 2 μ down to less than 0.1 μ, which by massage pressure are mech. entrained within the interstices of the stratum corneum. Particles < 0.5 μ do not require a carrier for entrainment. Delivery into mucosal epithelia is obtained by particles < 1 μ with delivery increasing with decreasing particle size. For example, in order to demonstrate the present invention, two compns. containing ibuprofen as the active agent were prepared Particles in both samples were identical (< 0.5 μm). However, sample A was water-free, while sample B contained 10% water. Transdermal absorption of the ibuprofen prepns. were compared using fresh bovine udder skin mounted on Franz diffusion cells at 37°. Approx. 30 mg of the ibuprofen preparation was applied to the skin and massaged into the skin using a vibratory massager. The water free sample (A) demonstrated a higher rate of absorption in less time than a similar formulation containing 10% water (sample B). In sample B the delivery was more than halved and the time rate of the delivery was found to be greatly reduced with delivery curve showing 16% over 12 h and only a further 7.5% delivery over the next 12 h.

L6 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 16 Nov 2001
ACCESSION NUMBER: 2001:833099 CAPLUS
DOCUMENT NUMBER: 135:362605
TITLE: Nutritional preparation comprising ribose and folic acid and medical use thereof

INVENTOR(S): Hageman, Robert Johan Joseph; Smeets, Rudolf Leonardus Lodewijk; Verlaan, George
PATENT ASSIGNEE(S): N.V. Nutricia, Neth.
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085178	A1	20011115	WO 2001-NL349	20010508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6420342	B1	20020716	US 2000-566381	20000508
EP 1282426	A1	20030212	EP 2001-930315	20010508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003532679	T	20031105	JP 2001-581831	20010508
US 2002183263	A1	20021205	US 2002-178736	20020625
US 6548483	B2	20030415		

PRIORITY APPLN. INFO.: US 2000-566381 A 20000508
WO 2001-NL349 W 20010508

AB Trauma, surgery, inflammation, subfertility, lactation problems, gut disorders, infant nutrition, cancer, arthritis and other joint problems, vascular problems and cardio- or cerebrovascular problems, ischemia, aging, impaired immune function, burns, sepsis, malnutrition, problems with liver or kidneys, malaria, cystic fibrosis, migraine, neurol. problems, respiratory infections, improvement of sports results, muscle soreness, drug intoxication and pain can be treated with a nutritional composition containing effective amts. of ribose and folic acid, optionally combined with other components such as niacin, histidine, glutamine, orotate, vitamin B6 and other components.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 27 Jul 2001
ACCESSION NUMBER: 2001:545470 CAPLUS
DOCUMENT NUMBER: 135:106772
TITLE: Use of ribose supplementation for increasing muscle mass and decreasing body fat in humans
INVENTOR(S): Vazquez, Lou; Hagerman, Scott; Butler, Terri
PATENT ASSIGNEE(S): Bioenergy Inc., USA
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052831	A1	20010726	WO 2001-US1964	20010119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002035069 A1 20020321 US 2001-766858 20010119
US 6525027 B2 20030225
PRIORITY APPLN. INFO.: US 2000-177139P P 20000120

AB Ribose administered to humans performing weight-training exercise provides more rapid increase in muscle mass and decrease in body fat than weight-training exercise without ribose.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 11 May 2001
ACCESSION NUMBER: 2001:338762 CAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also

disclosed.

L6 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 24 Dec 1999
ACCESSION NUMBER: 1999:811068 CAPLUS
DOCUMENT NUMBER: 132:44953
TITLE: Use of precursors of ATP for increasing energy in vivo
INVENTOR(S): St. Cyr, John; Johnson, Clarence A.
PATENT ASSIGNEE(S): Bioenergy Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965476	A2	19991223	WO 1999-US13720	19990617
WO 9965476	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6159942	A	20001212	US 1999-290789	19990412
CA 2334415	A1	19991223	CA 1999-2334415	19990617
CA 2334415	C	20040824		
AU 9945752	A	20000105	AU 1999-45752	19990617
EP 1087779	A2	20010404	EP 1999-928759	19990617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518321	T	20020625	JP 2000-554356	19990617
NZ 508478	A	20031031	NZ 1999-508478	19990617
EP 1745789	A1	20070124	EP 2006-12018	19990617
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
ZA 2000007582	A	20011218	ZA 2000-7582	20001218
US 2002072501	A1	20020613	US 2000-740255	20001218
US 6534480	B2	20030318		
US 2004087515	A1	20040506	US 2003-692338	20031023

PRIORITY APPLN. INFO.:		
US 1998-90001P	P	19980619
US 1999-290789	A	19990412
EP 1999-928759	A3	19990617
WO 1999-US13720	W	19990617
US 2000-221526P	P	20000728
US 2001-302200P	P	20010629
US 2001-917292	A1	20010727

AB Precursors of ATP are administered orally to increase intracellular ATP concentration as dietary supplements or for treatment of reduced energy availability resulting from strenuous phys. activity, illness or trauma. Pentose sugars are administered individually, mixed into dry food or in solution The preferred pentose is D-ribose, singly or combined with creatine, pyruvate, L-carnitine and/or vasodilating agents. Addnl., magnesium, electrolytes, fatty acids and hexose sugars can be used. The compns. and methods of this invention are especially beneficial to mammals having reduced energy availability or high energy demand. Administration of 5 mM ribose to rats increased the rate of ATP synthesis to 250 as compared with 48.6 nM/g/h for the controls. Oral administration of 250 mL iso-osmotic solution containing 10 g ribose three time/day for six days also increased exercise

capacity in normal healthy subjects.

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 12 Dec 1996
ACCESSION NUMBER: 1996:729783 CAPLUS
DOCUMENT NUMBER: 126:85324
TITLE: Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae
AUTHOR(S): Himmelreich, Ralf; Hilbert, Helmut; Plagens, Helga; Pirkl, Elsbeth; Li, Bi-Chen; Herrmann, Richard
CORPORATE SOURCE: Zenatrum Mol. Biologie Heidelberg, Univ. Heidelberg, Heidelberg, 69120, Germany
SOURCE: Nucleic Acids Research (1996), 24(22), 4420-4449
CODEN: NARHAD; ISSN: 0305-1048
PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The entire genome of the bacterium Mycoplasma pneumoniae M129 has been sequenced. It has a size of 816 394 base pairs with an average G+C content of 40.0 mol%. We predict 677 open reading frames (ORFs) and 39 genes coding for various RNA species. Of the predicted ORFs, 75.9% showed significant similarity to genes/proteins of other organisms while only 9.9% did not reveal any significant similarity to gene sequences in databases. This permitted us tentatively to assign a functional classification to a large number of ORFs and to deduce the biochem. and physiol. properties of this bacterium. The reduction of the genome size of M. pneumoniae during its reductive evolution from ancestral bacteria can be explained by the loss of complete anabolic (e.g. no amino acid synthesis) and metabolic pathways. Therefore, M. pneumoniae depends in nature on an obligate parasitic lifestyle which requires the provision of exogenous essential metabolites. All the major classes of cellular processes and metabolic pathways are briefly described. For a number of activities/functions present in M. pneumoniae according to exptl. evidence, the corresponding genes could not be identified by similarity search. For instance we failed to identify genes/proteins involved in motility, chemotaxis and management of oxidative stress.

L6 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 12 Apr 1995
ACCESSION NUMBER: 1995:480441 CAPLUS
DOCUMENT NUMBER: 122:222902
TITLE: Compositions of matter and methods for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
INVENTOR(S): Carniglia, Francis J.; Kenyon, Alan J.
PATENT ASSIGNEE(S): Roncari, Raymond A., USA
SOURCE: U.S., 22 pp. Cont.-in-part of U.S. 4,871,718.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5391550	A	19950221	US 1989-416248	19891002
US 4871718	A	19891003	US 1987-139288	19871229
AU 8817690	A	19890629	AU 1988-17690	19880615
AU 600139	B2	19900802		
CA 1325593	C	19931228	CA 1988-570187	19880623
JP 01175939	A	19890712	JP 1988-187078	19880728
JP 05020414	B	19930319		
ES 2045141	T3	19940116	ES 1988-309826	19881019
DK 8807260	A	19890630	DK 1988-7260	19881228

US 4923851 A 19900508 US 1989-415885 19891002
PRIORITY APPLN. INFO.: US 1987-139288 A2 19871229
AB Compns. for increasing the intracellular levels of ATP comprise amino acids, metabolites, electrolytes and/or pentose sugars. When applied to wounds, the composition increases the rate of wound repair and has an antimicrobial effect. When administered orally, the composition increases ATP blood levels and phys. performance levels. For example, a composition containing
L-glycine 8.9, L-arginine 35.4, DL-methionine 177.2, choline chloride 149.2, inositol 131.5, L-aspartic acid 131.5, L-tryptophan 38.4, L-phenylalanine 31.0, L-histidine 29.5, L-proline 22.2, D-ribose 131.5, and Mg phosphate 113.7 g was dissolved in a sterile isotonic solution to have 1% concentration The solution was applied to a single full-thickness excised wound on rats and the decrease in wound weight and increase in ATP levels in the tissue were observed

L6 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 30 Apr 1994
ACCESSION NUMBER: 1994:208571 CAPLUS
DOCUMENT NUMBER: 120:208571
TITLE: Substances penetrating the blood-brain barrier
INVENTOR(S): Naito, Albert T.
PATENT ASSIGNEE(S): Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05339148	A	19931221	JP 1992-160071	19920528

PRIORITY APPLN. INFO.: JP 1992-160071 19920528
AB Disclosed are substances that allow pharmaceuticals to pass through the blood-brain barrier. The substances are combinations of (1) ≥ 1 pure sugar selected from the group selected from the group comprising meso-erythritol, xylitol, D-(+)-galactose, D-(+)-lactose, L-(-)-fructose, D-(+)-glucose, D-(+)-arabinose, D-(-)-arabinose, D-(+)-maltose, D-(+)-glucosamine, D-mannosamine, and D-galactosamine, and (2) ≥ 1 amino acid selected from the group comprising glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and taurine.

=> d his

(FILE 'HOME' ENTERED AT 17:30:31 ON 29 SEP 2007)

FILE 'REGISTRY' ENTERED AT 17:31:01 ON 29 SEP 2007
L1 0 S RIBOSE AND CARNITINE
L2 7 S RIBOSE AND MAGNESIUM

FILE 'CAPLUS' ENTERED AT 17:32:45 ON 29 SEP 2007
L3 87 S RIBOSE AND CARNITINE
L4 24 S L3 AND MAGNESIUM
L5 2 S L4 AND DEPRESSION
L6 22 S L4 NOT L5

=> d his

(FILE 'HOME' ENTERED AT 17:30:31 ON 29 SEP 2007)